Baricent
Generic Name
Baricitinib
Manufacturer
Beacon Pharmaceuticals Ltd.
Country
Bangladesh
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| baricent 4 mg tablet | ৳ 40.00 | ৳ 280.00 |
Description
Overview of the medicine
Baricitinib is a Janus Kinase (JAK) inhibitor used to treat moderate to severe rheumatoid arthritis, moderate to severe atopic dermatitis, severe alopecia areata, and certain hospitalized adult patients with COVID-19.
Uses & Indications
Dosage
Adults
Rheumatoid Arthritis/Atopic Dermatitis/Alopecia Areata: Recommended starting dose is 2 mg once daily; may increase to 4 mg once daily if needed. COVID-19: 4 mg once daily for 14 days or until hospital discharge, whichever comes first.
Elderly
No specific dose adjustment required based on age alone. Monitor renal function.
Renal_impairment
Moderate (CrCl 30 to <60 mL/min): 1 mg once daily. Severe (CrCl <30 mL/min): Not recommended.
How to Take
Baricitinib tablets can be taken orally once daily, with or without food. Swallow the tablet whole.
Mechanism of Action
Baricitinib selectively and reversibly inhibits Janus kinase (JAK) enzymes, specifically JAK1 and JAK2. By inhibiting JAK, it modulates the signaling pathway of various cytokines and growth factors involved in inflammation and immune function.
Pharmacokinetics
Onset
Clinical improvement observed within a few weeks for rheumatoid arthritis; effects on COVID-19 related parameters are typically seen within days.
Excretion
Mainly renal excretion (approximately 75% unchanged), with about 20% excreted via feces.
Half life
Approximately 12-16 hours.
Absorption
Rapidly absorbed, peak plasma concentration (Cmax) achieved within approximately 1 hour. Absolute bioavailability is about 79%.
Metabolism
Primarily excreted unchanged. A minor portion undergoes oxidative metabolism via CYP3A4.
Side Effects
Contraindications
- •Known hypersensitivity to baricitinib or any component of the formulation.
- •Patients with severe active infections (e.g., active tuberculosis, localized infections, sepsis).
Drug Interactions
Probenecid
Concomitant administration with probenecid is expected to increase baricitinib exposure due to inhibition of OAT3 transporter. Reduce baricitinib dose to 2 mg/day if co-administered.
Live vaccines
Avoid use of live vaccines during and immediately prior to baricitinib therapy.
Immunosuppressants (e.g., other JAK inhibitors, biologics)
Avoid concomitant use due to increased risk of immunosuppression and infection.
Storage
Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.
Overdose
In case of overdose, there is no specific antidote. Treatment should be symptomatic and supportive. Baricitinib can be removed by hemodialysis.
Pregnancy & Lactation
Pregnancy Category C. Should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Advise breastfeeding mothers not to breastfeed during treatment and for at least 4 days after the last dose due to potential adverse effects on the breastfed infant.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
2 to 3 years from manufacturing date, check packaging for exact date.
Availability
Available in pharmacies and hospitals
Approval Status
FDA approved (initial approval 2018)
Patent Status
Patented (by Eli Lilly and Incyte)
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in
